These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 38199897)
1. Bispecific Antibodies in the Treatment of Multiple Myeloma. Zhou X; Xiao X; Kortuem KM; Einsele H Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897 [TBL] [Abstract][Full Text] [Related]
2. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting. Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181 [TBL] [Abstract][Full Text] [Related]
3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Cho SF; Anderson KC; Tai YT Front Immunol; 2018; 9():1821. PubMed ID: 30147690 [TBL] [Abstract][Full Text] [Related]
4. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622 [TBL] [Abstract][Full Text] [Related]
5. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838 [TBL] [Abstract][Full Text] [Related]
6. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E Expert Rev Hematol; 2024 Jul; 17(7):375-390. PubMed ID: 38770902 [TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. Lakshman A; Kumar SK Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922 [TBL] [Abstract][Full Text] [Related]
8. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. Kazandjian D; Kowalski A; Landgren O Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239 [TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future. Holstein SA; Grant SJ; Wildes TM J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687 [TBL] [Abstract][Full Text] [Related]